Immune Cells vs. Stem Cells: Two Different Systems, Two Different Jobs

Cell therapy marketing often blurs two entirely different biological systems into one promise. Stem cells and immune cells come from different lineages, do different jobs, are manufactured differently and are approved for different things. Confusing them is the reason patients sometimes expect an immune-cell infusion to regrow cartilage, or a stem cell infusion to clear a tumour.

Different jobs

Stem cells are the body's repair and renewal system. Their role is to maintain and replace tissue: skin turns over, blood is replenished, bone remodels. Mesenchymal stem cells in particular act as regulators of the local repair environment, secreting signals that reduce inflammation and support resident cells.

Immune cells are the body's defence and surveillance system. T cells, natural killer (NK) cells, dendritic cells, B cells and macrophages identify and remove infected cells, abnormal cells and pathogens. Their work is recognition and elimination, not construction.

Different origins

Immune cells derive from hematopoietic stem cells in the bone marrow, with T cells maturing in the thymus. Mesenchymal stem cells derive from connective-tissue compartments — bone marrow stroma, adipose tissue, umbilical cord. The two lineages diverge early and do not convert into one another.

Different clinical territory

Immune cell therapies dominate oncology. CAR-T products are approved for several blood cancers, checkpoint inhibitors reshape immune activity against solid tumours, and NK-cell and dendritic-cell approaches are in active trials. Stem cell therapies dominate structural and inflammatory disease: hematopoietic transplant for leukaemia and lymphoma, MSC products approved in some jurisdictions for graft-versus-host disease and Crohn's perianal fistulas, and a large body of investigational work in orthopedics and neurology.

Different evidence maturity

This is where the comparison becomes practically useful. Hematopoietic transplantation and CAR-T therapy both have decades or years of randomised and registrational data behind their approved uses. Most MSC applications, and most non-oncology immune-cell applications sold commercially, do not. A therapy being biologically plausible is not the same as it being demonstrated, and the two systems are at very different stages for different indications.

Where they genuinely overlap

There is real crossover. MSCs are immunomodulatory — that is precisely why they are studied in graft-versus-host disease and autoimmune conditions. And CD19 CAR-T cells, built for cancer, are now being tested in lupus and other autoimmune diseases. The overlap is at the level of immune regulation, not tissue regeneration.

The bottom line

Treat any offer that describes stem cells and immune cells as interchangeable components of a single wellness package as a warning sign. They are separate systems with separate evidence bases, and the right question is always which specific cell type, for which specific condition, with which specific published data.